Keywords

• Roflumilast
• 162401-32-3
• C17H14Cl2F2N2O3

Quick Details

• ProName: Roflumilast 162401-32-3 C17H14Cl2F...
• CasNo: 162401-32-3
• Molecular Formula: C17H14Cl2F2N2O3
• Appearance: detailed in specifcations
• Application: API ,OLED .AND SO ON
• DeliveryTime: 7days
• PackAge: as needed
• Port: china main port
• ProductionCapacity: 20 Metric Ton/Month
• Purity: 98%
• Storage: cool place
• Transportation: BY air or sea
• LimitNum: 1 Gram

Superiority

Our Services

1.Certificate Of Analysis (COA)

2.Material Safety Data Sheet (MSDS)

3.Route of synthesis (ROS)

4.Method of Aanlysis (MOA)

5.Nuclear Magnetic Resonance (NMR)

6.Packing pictures and loading video before loading

7.Free Sample

9.Factory audit

10.Strong after-sale service

Company information

Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.

Details

Roflumilast Basic information

Physical and chemical properties Phosphodiesterase 4 (PDE4) inhibitors Indications Pharmacokinetics Dosage Patents

Product Name:	Roflumilast
Synonyms:	ROFLUMILAST;3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide;B 9302-107;BY 217;BYK 20869;Daxas;Roflumilast / 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
CAS:	162401-32-3
MF:	C17H14Cl2F2N2O3
MW:	403.21
EINECS:	223-583-8
Product Categories:	All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;Roflumilast;Daxas;API
Mol File:	162401-32-3.mol

Roflumilast Chemical Properties

mp	158°C
storage temp.	Refrigerator
CAS DataBase Reference	162401-32-3(CAS DataBase Reference)

Safety Information

Hazard Codes	Xi
Risk Statements	36/37/38
Safety Statements	26

MSDS Information

 

Roflumilast Usage And Synthesis

Physical and chemical properties	White to light tan solid particles or crystalline powder. Odorless, slightly sweet taste, and soluble in water.
Phosphodiesterase 4 (PDE4) inhibitors	Roflumilast is a kind of oral and selective phosphodiesterase IV (PDE4) inhibitors. It is benzamides compound. And it is the only approved oral phosphatase IV (PDE-4) inhibitors that used in the treatment of respiratory diseases currently. It can selectively inhibit PDE4, block the signal transduction of inflammation, and then inhibit the damage to lung tissue caused by respiratory diseases such as COPD and asthma. It has proven to be a new mode of action in inhibiting COPD related-inflammation. Roflumilast is a once-daily tablet, and the first new type of drug for the treatment of severe COPD. It is also the first oral anti-inflammatory drugs for patients with COPD. Its unique nature can facilitate the better management of chronic obstructive pulmonary patients: when the combination with bronchodilator in the treatment of the most severe chronic obstructive pulmonary patients, roflumilast can offer the additional benefits of further reducing the symptoms and disease progression rates. Then it became the first drug of targeting particular phenotype of chronic obstructive pulmonary disease that is patients with severe airflow limitation and having a history of recurrent disease worsening associated with chronic cough and sputum. In 1993, Germany Altana Company successfully developed roflumilast for the first time. It is already the products of Switzerland Nycomed Pharmaceutical GmbH. In 2009, the company completed phase III clinical trials of roflumilast and submitted a listing application in Europe. The European Union approved the roflumilast (Daxas) to the market on July 6, 2010. Then Nycomed signed a cooperation agreement with Forest Lab. Forest Lab invested $600 million to obtain the rights to sell daxas in the US, and it was responsible for the application of roflumilast in the FDA and roflumilast’s promotion and sale. While Nycomed will retain the right to sell the drug in Europe and other regions of the world. The above information is edited by the Chemicalbook of Ge Qian.
Indications	Roflumilast can be used for the prevention and treatment of respiratory disease, and used for the treatment of severe chronic obstructive pulmonary disease (COPD) and excessive mucus cough bronchitis, asthmatic bronchitis, bronchial asthma, respiratory tract associated with abnormal secretion of acute and chronic bronchitis, air sacculitis, etc.  Chronic obstructive pulmonary disease (referred to as "COPD"), is chronic lung disease that characterized by incompletely reversible airflow obstruction. It is usually manifested clinically recurrent cough, sputum, dyspnea and other symptoms. That usually shows progressive progress features, including the vast majority of chronic bronchitis and emphysema. As the disease progresses, it will lead to airway remodeling, and ultimately develop to irreversible airflow obstruction, or coexist with asthma overlap. Therefore, improving the control of airflow obstruction and inflammation is the main goal of drug research at home and abroad. Chronic obstructive pulmonary disease (COPD) is one of progressive and life-threatening lung disease and one of the human health "killer". It makes dyspnea, loss of activity. The disease typically includes chronic bronchitis